home > drugs a-z list > increlex (mecasermin [rdna origin] injection) drug center > increlex (mecasermin [rdna origin] injection) drug - overdosage and contraindications

There is no clinical experience with overdosage of INCRELEX® (mecasermin [rdna origin] injection) . Based on known pharmacological effects, acute overdosage may lead to hypoglycemia. Long-term overdosage may result in signs and symptoms of acromegaly. Treatment of acute overdose of INCRELEX® (mecasermin [rdna origin] injection) should be directed at reversing hypoglycemia. Oral glucose or food should be consumed. If the overdose results in loss of consciousness, intravenous glucose or parenteral glucagon may be required to reverse the hypoglycemic effects.

Active or Suspected Neoplasia

INCRELEX® (mecasermin [rdna origin] injection) is contraindicated in the presence of active or suspected malignancy, and therapy should be discontinued if evidence of malignancy develops.

Known Hypersensitivity

INCRELEX® (mecasermin [rdna origin] injection) should not be used by patients who are allergic to mecasermin (rhIGF-1) or any of the inactive ingredients in INCRELEX® (mecasermin [rdna origin] injection) , or who have experienced a severe hypersensitivity to INCRELEX® [see WARNINGS AND PRECAUTIONS and ADVERSE REACTIONS]

Intravenous Administration

Intravenous administration of INCRELEX® (mecasermin [rdna origin] injection) is contraindicated.

Closed Epiphyses

INCRELEX® (mecasermin [rdna origin] injection) should not be used for growth promotion in patients with closed epiphyses.

Last reviewed on RxList: 4/18/2011
This monograph has been modified to include the generic and brand name in many instances.